Triple negative breast cancer (TNBC) is an aggressive breast cancer with historically poor
outcomes, primarily due to the lack of effective targeted therapies. The tumor molecular …

Breast cancer susceptibility gene 1 (BRCA1) is a tumor suppressor gene, which is mainly
involved in the repair of DNA damage, cell cycle regulation, maintenance of genome …

Purpose: Prognostic value of pathologic complete response (pCR) and extent of pathologic
response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy …

The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin
derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The …

Important results are emerging from clinical trials showing that surgery followed by
chemotherapy might not be the optimal strategy to maximise a patient's chance of survival …

Background Pathological complete response (pCR) is associated with improved prognosis
in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen is unclear …

Purpose: Triple-negative breast cancer (TNBC) requires the iden-tification of reliable
predictors of response to neoadjuvant chemotherapy (NACT). For this purpose, we aimed to …

Abstract Background Nicotinamide N-methyltransferase (NNMT) is overexpressed in various
human tumors and involved in the development and progression of several carcinomas. In …

Previous studies have shown that the addition of carboplatin to neoadjuvant chemotherapy
improved the pathologic complete response (pCR) rate in patients suffering from triple …

Immunosuppressive elements within the tumor microenvironment, such as tumor-associated
macrophages (TAM), can present a barrier to successful antitumor responses by cytolytic T …